Table of Contents
In 2024 Kenya bought roughly $705m of pharmaceutical products from abroad and sold only a fraction of that overseas. The country's drug problem is not that Kenyans lack appetite for medicine. They have plenty. What they lack is the factories to make it.
Kenya's pharmaceutical market is usually framed as a question of healthcare demand. It is better read as a question of industrial policy. The demand already exists; it is simply met by suppliers in India, China and Europe. For an investor the prize is not in creating new buyers but in taking a slice of a market that is already here — through local manufacturing, public procurement and tighter command of the supply chain.
How big is the gap between what Kenya makes and what it needs?
Start with the size of the prize. Kenya's pharmaceutical market is worth about KES 76 billion, and imports swallow roughly 70 percent of it. The country has more than 30 licensed drug makers — Beta Healthcare, Cosmos and Dawa among them — but together they meet only about a third of local demand. The rest arrives from India, China and Europe.
The sharper measure is essential medicines. A government assessment found that local firms make only 220 of the 1,096 formulations on the Kenya Essential Medicines List, about 20 percent. More than four-fifths of the drugs the state itself calls essential are not made in Kenya at all.
The plants that exist are not the problem. They simply run short of their potential, with output for tablets and capsules sitting well below capacity. This is no blank sheet. It is an established industry that was never built to scale.
How is procurement becoming industrial policy?
The shift began with a presidential directive. In October 2023 the government set a target: at least half the medicines on the Kenya Essential Medicines List should be made at home by 2026. Against a local base of roughly 20 percent, that is a steep climb. It is also the space investors are being invited to fill — the gap between where production sits and where the state wants it.
The telling part is how the government means to get there. It is using its own chequebook. In 2023/24 KEMSA, the state procurement agency, planned to buy pharmaceutical drugs worth about KES 5.4 billion, of which some KES 3 billion was reserved for local manufacturers. It also agreed to stop importing products that at least three Kenyan firms already make. Public money is being turned into a guaranteed market, a demand floor a domestic producer can plan against.
This is procurement as industrial policy, and the state presents it as a matter of health security. By writing local-preference rules into how it spends, the government is trying to drag the industry off imported supply and onto its own production lines.
Where is the real bottleneck?
The trouble sits in the middle of the chain, not at either end. Kenya's drug makers can press tablets and fill capsules, but they buy almost all their active pharmaceutical ingredients (APIs) and excipients abroad, mostly from India and China. That single dependence colours everything else. When the shilling weakens or a supplier in Mumbai raises prices, a Nairobi factory feels it at once.
The rest of the cost stack is unforgiving too. Power and packaging are expensive, skilled staff are scarce, and credit is dear. Registration backlogs and slow API approvals keep finished medicines off the shelves even when a plant is ready to make them. The real test is mundane: can a Kenyan firm register, finance, source, certify and ship a drug at a price that beats an import? For now, mostly, it cannot.
What does the trade data show?
A smaller import bill can flatter to deceive. Between January and September 2025 Kenya spent about KES 62 billion on medicinal and pharmaceutical imports, down 22 percent from KES 79.6 billion a year earlier. Yet the tonnage barely moved; volumes edged up 1.2 percent. Kenya was not buying less foreign medicine. It was buying cheaper foreign medicine — more generics and keener prices — not local output in place of imports.
That is the squeeze. A domestic producer carrying costly credit, imported APIs and an erratic order book competes against a tide of cheap imports. Encouragement alone will not change it. Unless policy shifts the relative economics, through tariffs, preference rules or cheaper financing, compliant local firms will keep losing on price to the very imports the state wants to replace.
Where are the openings for investors?
Not in pharmacies. The money is in the middle of the chain: generics manufacturing, the making of APIs and intermediate inputs, and upgrading plants to Good Manufacturing Practice standards. Around those sit quieter plays in quality-control systems, contract manufacturing, specialised packaging, warehousing and distribution. The Ministry of Health has also signalled a move to digital track-and-trace, using serialisation to fight counterfeits, another niche for capital.
The winners will be firms that can make essential drugs to global standards, lock in steady offtake and manage working capital through the politics of industrial policy. Kenya's drug problem has changed shape. It is no longer a question of demand, which is plentiful, but of supply, which is thin. Closing that gap is slow, capital-hungry work, and that is why the sector now needs patient institutional money more than another round of speeches.
